Progesterone (Hydroxyprogesterone Caproate / "Strone AQ") in the Context of Decreased Fetal Movement

What is "Strone AQ"?

Strone AQ refers to a progesterone aqueous injection — commonly hydroxyprogesterone caproate (17-OHPC) or a similar progestational agent. It is used as an intramuscular injection during pregnancy.

Clinical Concern: Does Progesterone Cause Decreased Fetal Movement?

Progesterone / hydroxyprogesterone caproate can cause decreased fetal movement — this is a recognized side effect. Here's the mechanism and clinical significance:

Mechanism

Progesterone is a smooth muscle relaxant and CNS depressant. Its sedating properties can suppress fetal neurological activity, leading to:

Reduced gross body movements
Reduced fetal breathing movements
Potential false-positive "decreased fetal movement" concern

Clinical Relevance

When a patient on Strone AQ (progesterone injection) reports decreased fetal movement, the differential includes:

Drug-related fetal sedation — progesterone-induced reduction in fetal activity (benign, dose/timing related)
True fetal compromise — placental insufficiency, hypoxemia, acidemia (requires urgent evaluation)

⚠️ You cannot attribute decreased fetal movement solely to progesterone therapy without ruling out fetal compromise.

Management of Decreased Fetal Movement in a Patient on Progesterone Injection

Step 1 — Maternal Kick Counting

Ask the patient about timing relative to injection:

If DFM occurred within hours of IM injection, drug-related sedation is possible
Persistent or progressive DFM requires formal evaluation regardless

Step 2 — Non-Stress Test (NST)

Assess fetal heart rate reactivity
Progesterone may cause reduced variability and fewer accelerations — a non-reactive NST requires further assessment

Step 3 — Biophysical Profile (BPP)

Evaluate 5 parameters (each = 2 points, max 10/10):

Parameter	Normal (2 pts)
Fetal breathing	≥1 episode ≥30 sec in 30 min
Gross body movements	≥3 discrete movements in 30 min
Fetal tone	≥1 active extension/flexion
Amniotic fluid	Single deepest pocket ≥2 cm
NST (reactive)	≥2 accelerations in 20 min

BPP 8–10/10 = reassuring
BPP 4–6/10 = equivocal → repeat in 24 hours or consider delivery based on GA
BPP 0–2/10 = abnormal → consider immediate delivery

Step 4 — Umbilical Artery Doppler

If fetal growth restriction (FGR) suspected — assess for absent/reversed end-diastolic flow.

Role of Progesterone (17-OHPC) in Preterm Prevention

Per Goodman & Gilman's Pharmacological Basis of Therapeutics:

"Hydroxyprogesterone caproate at 250 mg administered weekly by intramuscular injection has been shown to reduce preterm birth by about one-third in women with a prior preterm singleton birth."

Per Creasy & Resnik's Maternal-Fetal Medicine: Decreased fetal movement is itself an indication for fetal surveillance (NST/BPP) regardless of the cause, alongside oligohydramnios, growth restriction, and maternal medical complications.

Key Points Summary

Aspect	Detail
Drug	Hydroxyprogesterone caproate 250 mg IM weekly ("Strone AQ")
Indication	Prevention of recurrent preterm birth
Effect on fetal movement	Can transiently ↓ fetal activity due to CNS sedation
Safe to assume drug-caused?	No — always rule out true fetal compromise
First investigation	NST
Gold standard assessment	Biophysical profile (BPP)
Reassuring BPP score	≥8/10
Delivery threshold (term)	BPP ≤4/10 or persistent concern

Sources: Creasy & Resnik's Maternal-Fetal Medicine; Goodman & Gilman's Pharmacological Basis of Therapeutics, 13e

This is a shared conversation. Sign in to Orris to start your own chat.